Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day.
about
Corticosteroids for the management of cancer-related pain in adultsMechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factorMedical management of brain tumors and the sequelae of treatment.Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanismsDexamethasone alleviates tumor-associated brain damage and angiogenesisDexamethasone-Mediated Activation of Fibronectin Matrix Assembly Reduces Dispersal of Primary Human Glioblastoma CellsInhibition of SUR1 decreases the vascular permeability of cerebral metastases.Through the patient's eyes: the value of a comprehensive brain tumor center.ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases.Effects of progesterone vs. dexamethasone on brain oedema and inflammatory responses following experimental brain resection.Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.Symptomatic management and imaging of brain metastases.EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis.Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy.Use of dexamethasone in patients with high-grade glioma: a clinical practice guidelineCorticosteroids in brain cancer patients: benefits and pitfalls.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Bevacizumab for the treatment of recurrent glioblastoma.Perioperative management of patients with lung carcinoma and cerebral metastases.Current standards in the management of cerebral metastases.The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-ChronicDexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma.Collaboration in the presence of cerebral edema: The complications of steroids.Treating gliomas with glucocorticoids: from bedside to bench.Clinical management of brain metastasis.The evidence base of palliative medicine: is inpatient palliative medicine evidence-based?CNS metastasis in primary breast cancer.Role of corticosteroids in palliative care.The use and toxicity of steroids in the management of patients with brain metastases.Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline.Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners.Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.Corticosteroid-use in primary and secondary brain tumour patients: a review.Optimal management of brain metastases from breast cancer. Issues and considerations.Potential of glyburide to reduce intracerebral edema in brain metastases.Brain metastases: an overview.Corticosteroid use in neuro-oncology: an update.
P2860
Q24186400-EBFB62A6-B74F-4AB5-A141-A8AC939EA51AQ24561970-FC1699D9-5773-4380-963C-FD73913BA536Q26992174-0DFD51F0-956F-4CE0-B901-446E4ED27850Q28075735-A4805903-8A7A-43C7-AA09-AAB7AA6A952AQ28542092-BA6E4871-2D61-4E07-8D98-727C3C9B2BA4Q28547328-377E5EC0-CBFA-476B-A3A3-6205A340C2E8Q30273936-AE731760-E326-43C4-849E-FD7401B60F5AQ30364757-9AE36DAD-8B68-435D-8403-C61744143279Q30833655-4173A91D-9089-4B06-B172-71827DFD4B0BQ30840745-C54983CF-48C4-4717-89F1-4FD8366C031DQ30934034-B1F63529-2D79-416C-9399-D6053AEA4C45Q31010312-74F52223-B82C-436B-8990-DE821618AFC8Q33249813-72905BDA-AE9D-48E1-9211-FCAD3F73B139Q33529158-B204E6E5-8EB5-4445-B106-21CE54CAE088Q33742612-FC76D216-0D55-4F09-8A61-A7BDA1700E1EQ33763941-25F7E715-10DA-4126-AA9B-7447F8CF9321Q34191990-20FD0F08-DF3E-4752-8DCC-D03B9E0965B0Q34663877-AEADA64E-C374-4053-80EC-A9A48CE69B06Q34982777-A8483874-31CE-47EA-89A0-0E4D97BB7A7BQ35146981-6483B80B-E34E-416B-BAA3-D020C043E086Q35687738-2C6B7DF4-7512-4891-A7BF-296247D7C731Q35815301-A605001D-5E26-4DC7-BE8F-20C793C2DD3EQ35863183-15E620F0-0011-4E78-BDDA-24CB3094BFE0Q35999184-7B415C54-D10F-48CD-8DB1-ECD64B4DD85DQ36541689-5E2CD4AC-84B0-44BA-9D24-792CBBC427E8Q36896269-0D42A34A-D229-4210-8CF6-7E30919E16B6Q36974038-FD9C0C1C-B0E4-42C3-A320-CAC69E5CD59BQ37004668-3DC55418-FEA2-4B94-9705-1765661ADDF3Q37010936-788590E3-6152-4661-8361-80481F7A34BBQ37078927-C8973C9A-B5E0-403E-8AF8-2AA966CE3F6AQ37180426-8D5491F3-94C5-460B-807F-4081C76D5946Q37643538-D3B0A643-A3D8-4539-86E2-5AA94A4FE4B2Q37698300-70B55A83-356D-4CAE-9E18-4C4F896F3654Q37764968-E733BC96-1C6B-4139-943A-81A72336D981Q37766531-5C5AD1D3-2275-4DA3-BE39-4324FAEA15CAQ37942476-49D9FE29-7EE1-4C95-BB20-4CA3D884565AQ38067340-8ACC29BA-9B66-4621-AA49-83761F0793C2Q38189496-44A99FB2-3F66-4902-9185-092288442C0FQ38317417-123611D4-D205-46D2-B6D6-C23109457F56Q38512587-4410F2CB-DFBD-4E9A-85AA-10D74BF97A15
P2860
Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Dose-effect relationship of de ...... es of 4, 8, and 16 mg per day.
@en
type
label
Dose-effect relationship of de ...... es of 4, 8, and 16 mg per day.
@en
prefLabel
Dose-effect relationship of de ...... es of 4, 8, and 16 mg per day.
@en
P2093
P356
P1433
P1476
Dose-effect relationship of de ...... es of 4, 8, and 16 mg per day.
@en
P2093
Hovestadt A
Verbiest HB
van Putten WL
van Vliet JJ
P304
P356
10.1212/WNL.44.4.675
P407
P577
1994-04-01T00:00:00Z